L
Landos Biopharma
A clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease
About Landos Biopharma
Landos Biopharma is a clinical-stage biotechnology company focused on developing novel, first-in-class oral therapeutics for autoimmune diseases. The company operates in the biopharmaceutical market, targeting conditions such as ulcerative colitis and Crohn's disease. Landos Biopharma's lead asset, BT-11, is a small molecule currently in Phase 2 trials for ulcerative colitis, with plans for additional trials in Crohn's disease. Another promising candidate, NX-13, is in Phase 1 studies for inflammatory bowel disease. The company aims to transform the standard of care by identifying novel pathways at the interface of immunity and metabolism, providing safer and more effective treatment options for patients. Landos Biopharma generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. The company's diverse team fosters an environment of innovation, driving forward its mission to improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Ashtabula, United States
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Drug Development, Gastroenterology, Autoimmune, Inflammatory Diseases, Biotech and Pharma, Hard Tech, medical testing, DT and LS
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2024 | $138M | — | AbbVie | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jan 2023 | $17M | — | Perceptive Advisors | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Landos Biopharma is 280 monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Perceptive Advisors
RTW Investments- PGPBM Capital Group
Other known investors3 additional known investors
AbbVie
Osage University Partners
Xontogeny
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Landos Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Landos Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.